Merakris Therapeutics, Inc.
Roger Ilagan, PhD has held several key positions in the field of regenerative medicine and biotechnology. Roger currently serves as the Vice President, Research and Development at Merakris Therapeutics, Inc. Roger's expertise includes overseeing scientific development, establishing research collaborations, and focusing on pulmonary diseases. With a Ph.D. in Cell Biology from Duke University, Roger's extensive experience includes roles in companies like Tavanta Therapeutics, Lung Biotechnology PBC, and United Therapeutics, where Roger managed research initiatives for tissue-engineered organs and gene therapy. Prior to their current role, Roger worked on bioprocess R&D and tissue regeneration at companies like LifeCell and Tengion.
Merakris Therapeutics, Inc.
1 followers
A pioneer in biotechnology, Merakris Therapeutics, based in Research Triangle Park, North Carolina, is a leader in researching, developing, and marketing regenerative healthcare products. We are pioneering commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Our vision is to improve global patient care and outcomes through the pioneering and innovation of cellular regenerative biotechnologies. Merakris Therapeutics strives to: • Be a leader in the research and development of regenerative medicine. • Deliver effective medical therapies that require fewer treatments and help to improve patient outcomes, while reducing the overall cost of care. • Educate patients and healthcare providers about the benefits of alternative therapies and regenerative medicine in comparison to standard or more invasive treatment options.